Многоцентровое исследование эффективности неоадъювантной терапии САРОХ/бевацизумаб у неоперабельных больных с метастазами колоректального рака в печени

Проанализированы результаты многоцентрового исследования II фазы, в котором показана эффективность и безопасность комбинации режима CAPOX с бевацизумабом при неоадъювантной терапии не подлежащих хирургическому лечению пациентов с метастазами колоректального рака в печени: резектабельность последних была достигнута в 44% случаев, 12-месячная выживаемость: общая – 96%, безрецидивная – 50%. Ключевые слова: колоректальный рак, метастазы в печени, бевацизумаб, капецитабин, оксалиплатин.The results of multicentre study of II phase are analyzed. The efficacy and safety of combined regimen CAPOX + bevacizumab in adjuvant therapy of patients not selected for upfront resection and with colorectal cancer metastasis in liver is demonstrated. The respectability was achieved in 44% of cases, 12-month survival, overall, survival 96%, without relapse 50%. Key Words: bevacizumab, capecitabine, colorectal cancer, liver metastases, oxaliplati

Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes?

Despite recent advances in diagnosis and treatment of certain cancers such as breast, colon and prostate cancers, pancreatic cancer remains a deadly malignancy with a mortality rate almost equal to its incidence. The survival benefit after all possible medical interventions is still disappointing for the majority of patients with pancreatic cancer. Improving the quality of life and increasing survival remain as the key objectives of pharmacogenomics and clinical investigation in pancreatic cancer. There are several notable genetic loci (e.g., RRM1, CDA, DPYD, UGT1A1) known to predict the toxicity of drugs used in pancreatic cancer such as gemcitabine, capecitabine, platinum agents and irinotecan. Other genes are associated with efficacy of these drugs (e.g., HuR, DCK, TS, ERCC1), although prospective validation of their clinical utility is still required. This paper presents the latest research advances in pharmacogenomics of pancreatic cancer with a view to molecular guidance for clinical diagnosis and individualized patient care. © 2010 Bentham Science Publishers Ltd